知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.015 秒)

    Dosage Regimen for a Controlled-Release PTH Compound
    3.
    发明公开
    Dosage Regimen for a Controlled-Release PTH Compound 审中-公开

    公开(公告)号：US20230321198A1

    公开(公告)日：2023-10-12

    申请号：US18176372

    申请日：2023-02-28

    申请人： ASCENDIS PHARMA BONE DISEASES A/S

    发明人： Kennett Sprogøe ,  Felix Cleemann ,  Guillaume Maitro ,  Mathias Krusch ,  Thomas Wegge ,  Joachim Zettler

    IPC分类号： A61K38/29 ,  A61K9/00 ,  A61K9/16 ,  A61K47/60

    CPC分类号： A61K38/29 ,  A61K9/0019 ,  A61K9/1647 ,  A61K47/60 ,  A61K47/34

    摘要： The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTII compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, pharmaceutical composition comprising at least one controlled-release PTII compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, wherein said pharmaceutical composition is administered no more frequent than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTII 1-84 administered every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.

    Dosage Regimen for a Controlled-Release PTH Compound
    6.
    发明公开
    Dosage Regimen for a Controlled-Release PTH Compound 审中-公开

    公开(公告)号：US20230248836A1

    公开(公告)日：2023-08-10

    申请号：US18063294

    申请日：2022-12-08

    申请人： ASCENDIS PHARMA BONE DISEASES A/S

    发明人： Kennett Sprogøe ,  Felix Cleemann ,  Guillaume Maitro ,  Mathias Krusch ,  Thomas Wegge ,  Joachim Zettler

    IPC分类号： A61K47/60 ,  A61K47/54

    CPC分类号： A61K47/60 ,  A61K47/54 ,  A61K47/545

    摘要： The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, wherein said pharmaceutical composition is administered no more frequent than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.

    Starting Dose of PTH Conjugates
    7.
    发明申请
    Starting Dose of PTH Conjugates 有权

    公开(公告)号：US20210196801A1

    公开(公告)日：2021-07-01

    申请号：US17055695

    申请日：2019-05-17

    申请人： Ascendis Pharma Bone Diseases A/S

    发明人： Kennett Sprogøe ,  David Brian Karpf ,  Claus Strange

    IPC分类号： A61K38/29 ,  A61K47/54 ,  A61K47/60

    摘要： The present invention relates to a PTH conjugate, in which a PTH moiety is reversibly conjugated to a polymeric moiety or fatty acid-based moiety, or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said PTH conjugate or pharmaceutically acceptable salt thereof for use in the treatment, control, delay or prevention of a disease that can be treated, controlled, delayed or prevented with PTH, wherein the starting dose ranges from from 0.8 to 4.9 nmol/day and to the respective methods of treatment.

    Controlled-Release PTH Compound
    8.
    发明公开
    Controlled-Release PTH Compound 审中-公开

    公开(公告)号：US20230381284A1

    公开(公告)日：2023-11-30

    申请号：US18355223

    申请日：2023-07-19

    申请人： ASCENDIS PHARMA BONE DISEASES A/S

    发明人： Kennett Sprogøe ,  Felix Cleemann ,  Guillaume Maitro ,  Mathias Krusch ,  Thomas Wegge ,  Joachim Zettler

    IPC分类号： A61K38/29 ,  A61K9/00 ,  A61K9/16 ,  A61K47/60 ,  A61K47/54

    CPC分类号： A61K38/29 ,  A61K9/0019 ,  A61K9/1647 ,  A61K47/60 ,  A61K47/545 ,  A61K47/54 ,  A61K47/34

    摘要： The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, wherein said pharmaceutical composition is administered no more frequent than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.